ACCESS Newswire

Cannabis Global, Inc.

20.7.2021 14:03:54 CEST | ACCESS Newswire | Press release

Share
Cannabis Global Comments on the Publication of its Cannabis Nanotechnology Patent Application

LOS ANGELES, CA / ACCESSWIRE / July 20, 2021 / Cannabis Global, Inc. (OTC PINK:CBGL), a licensed Los Angeles-based manufacturer and distributor in the cannabis sector today releases the details of its non-provisional patent application for electrosprayed and electrospun cannabinoid compositions. The invention addresses new methods for the creation of highly bioavailable and ultra-fast acting cannabinoids for use in beverages, food, topical, and other applications and demonstrates the Company's ability to incorporate Delta-9-tetrahydrocannabinol (THC), Cannabidiol (CBD), and Tetrahydrocannabivarin (THC-V) into unique nanoparticles and nanofibers using pharmaceutical grade electrospraying and electrospinning techniques.

The now publicly available patent application outlines several breakthroughs created by the Company's Project Varin, including, but not limited to:

  1. Slow-release cannabinoid nanofibers and nanoscale particles using edible gelatin created from food-grade acetic acid-water-based solutions. The Company believes this invention will allow product formulators to tailor products with selectable release parameters. The results also confirmed agglomeration can be fostered and/or avoided and suggest that particles can remain suspended over long periods of time, which could facilitate innovative beverage formulations.
  2. Quick dissolving THC and CBD nanofiber scaffolds were developed that almost instantly dissolved in water. This technology was specifically designed to be used in ultra-fast-acting cannabinoid delivery applications.
  3. Tetrahydrocannabivarin (THC-V) nanofibers at 75-nanometers at 70% concentrations that were readily soluble in water. Considering the very high cost of obtaining this rare cannabinoid, the use of THC-V in a nano format could enable a host of unique product formulations. The average width of the fibers was from about 200 nm to 400 nm, which have around 6,000 times more surface areas than would be available if present in spherical form.
  4. Development of electrospraying and electrospinning techniques utilizing food-grade cellulose for delayed release of cannabinoids.

"We believe what we have created is highly significant to the cannabis industry, especially as nationwide cannabis legalization looms on the horizon," commented Arman Tabatabaei, CEO of Cannabis Global. "These new cannabinoid delivery technologies were designed to allow beverage, food, and cosmetic product formulators design into products fast or slow release parameters cannabinoids and/or to use significantly less cannabinoids in products while achieving similar or meaningfully greater efficacy. Our patent filing covers not only the new processes developed to create the new forms of cannabinoids but also the nanoparticles and nanofibers using the outlined processes and ingredients. We are especially proud of the fact we have been able to use food-grade ingredients in many of the formulations allowing consumer product companies to produce the clean labels consumers are increasingly desiring."

The Company has yet to be issued any protections for the U.S. Patent and Tradmarket Office for its inventions. Since the beginning of the Company's Porject Varin, Cannabis Global has filed six provision patent applications and three non-provisional applications. The Patent Applications outlined in this relese is Pub. No.: US 2021/0205224 A1, published on Jly 8, 2021.

Psychoactive Cannabis and Federal Law
Psychoactive Cannabis containing greater than 0.3% THC is a Schedule 1 managed substance and is against the law underneath federal regulation, particularly the Controlled Substances Act (21 U.S.C. § 811). Even in states which have legalized the use of psychoactive hashish for medical and/or leisure use, its sale and use stay violations of federal regulation. The illegality of psychoactive hashish underneath federal regulation preempts state legal guidelines that legalize its use. Strict enforcement of federal regulation concerning psychoactive hashish would materially impression our enterprise.

About Cannabis Global, Inc.
Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport and tracking, and are the developer and marketer of the Hemp You Can Feel™ brand. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

Forward-Looking Statements
This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "expect", "project", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please contact:
Arman Tabatabaei
IR@cannabisglobalinc.com
+1-(310)-986-4929

IR Contact:
Stuart Smith
https://www.smallcapvoice.com/
ssmith@smallcapvoice.com

SOURCE: Cannabis Global, Inc.



View source version on accesswire.com:
https://www.accesswire.com/656219/Cannabis-Global-Comments-on-the-Publication-of-its-Cannabis-Nanotechnology-Patent-Application

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics16.9.2026 13:00:00 CEST | Press release

Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune disease, transplantation and oncology Union of two companies brings together Santersus' NucleoCapture® technology, designed to physically remove NETs from circulation, with Xenetic's DNase technology, designed to enzymatically degrade NETs in tissue Joint pipeline includes four first-in-class programs, including pivotal-stage programs in sepsis and systemic lupus erythematosus (SLE), both of which have received FDA Breakthrough Device Designation Companies to host Business Update Conference Call and Webcast Today, Wednesday, September 16th at 8:30 AM ET FRAMINGHAM, MA / ACCESS Newswire / September 16, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company advancing its Deoxyribonuclease ("DNase") technology, and Santersus AG ("Santersus"), a privately held

DataTracks Completes First Live GloBE Filing Cycle, Delivering Close to 500 Pillar Two Filings Across 10+ Jurisdictions16.9.2026 11:15:00 CEST | Press release

HMRC-authorised provider completes close to 500 Pillar Two filings, including more than 150 GIRs, for 160+ clients across 10+ jurisdictions WEYBRIDGE, GB / ACCESS Newswire / September 16, 2026 / DataTracks, recognised by HMRC as an authorised software provider supporting UK Pillar Two submissions, has completed its first live BEPS Pillar Two filing cycle, delivering close to 500 filings, including more than 150 GIRs, across 10+ jurisdictions for more than 160 clients. The milestone caps two decades of work in regulatory reporting. The cycle spanned GloBE Information Returns (GIR), domestic top-up tax returns under local QDMTT (Qualified Domestic Minimum Top-up Tax) regimes, UK Overseas Return Notifications (ORNs), and other jurisdiction-specific returns and notifications. Several jurisdictions in this cycle, including the Netherlands and Luxembourg, require similar notifications confirming where the GIR was filed centrally, under their own local terms. DataTracks filed each return dire

Hydrosat Unveils Osiris Constellation, The Future of Thermal Intelligence16.9.2026 08:00:00 CEST | Press release

Next-generation satellite constellation will combine high-resolution thermal imaging with broad-area coverage and daily revisit to support governments, businesses, and researchers worldwide. PARIS, FR / ACCESS Newswire / September 16, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, today announced Osiris, its next-generation Earth observation constellation designed to deliver wide-area, high resolution intelligence for water and food security, critical infrastructure, and national security missions. At the core of each Osiris satellite is Hydrosat's next-generation thermal infrared payload, developed to collect high-resolution thermal data across exceptionally wide areas. Operating across three longwave infrared bands, the payload will capture imagery at 25-meter native resolution over 160-kilometer to 340-kilometer swath widths, addressing one of Earth observation's biggest challenges between spatial detail and collection scale. This

Innodata Appoints Admiral Michael S. Rogers, Former NSA Director and Commander of U.S. Cyber Command, to Its Board of Directors15.9.2026 16:35:00 CEST | Press release

One of the nation's most senior cyber and intelligence leaders will help guide Innodata's strategy as it accelerates Federal and cyber-related AI initiatives. NEW YORK, NY / ACCESS Newswire / September 15, 2026 / INNODATA INC. (Nasdaq:INOD) today announced the appointment of Admiral Michael S. Rogers, U.S. Navy (Retired) - the former Director of the National Security Agency (NSA) and Commander of U.S. Cyber Command - to its Board of Directors, effective immediately. One of the highest-ranking cyber and intelligence leaders ever to serve the United States, Admiral Rogers joins at a pivotal moment, as the AI industry, enterprises and the Federal government alike wrestle with how to make increasingly capable AI systems safe and secure - and as Innodata accelerates its Federal practice launched last Fall and launches new capabilities designed specifically to make AI systems demonstrably safe and secure. "There is no one better positioned to help guide this chapter of Innodata's growth than

MicroVision Showcases Expanding Perception Portfolio at IAA Transportation 202615.9.2026 15:20:00 CEST | Press release

New Perception Platform, next-generation MOVIA S, HALO, FMCW technology, and commercial vehicle concept demonstrate MicroVision's Lidar 2.0 strategy in action REDMOND, WA AND HANOVER, GER / ACCESS Newswire / September 15, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception technologies, is showcasing the expanding breadth of its sensing and perception portfolio this week at IAA Transportation 2026, demonstrating how lidar hardware, perception software, and open sensor integration can work together to address increasingly complex applications across transportation and autonomy. At the center of MicroVision's IAA presence is the newly introduced MicroVision Perception Platform™, a flexible, modular architecture designed to allow sensing and perception configurations to be tailored to the requirements of individual applications. Throughout IAA, MicroVision is bringing that strategy to life through a series of technology demonstrations and reference concepts spanning pa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye